Epidarex

Epidarex Capital – Catalyzing innovation in health science and technology

Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab

Interim data shows broad hematologic correction including improved hemoglobin levels and reduction in LDH CRESTWOOD, KY. and WALTHAM, MA., April 16, 2018 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of…

Prof Dorien Peters Joins Mironid’s SAB

March 26, 2018 – Mironid is delighted to announce the appointment of Prof Dorien Peters to our Scientific Advisory Board Prof. Dr. Dorien Peters is a molecular geneticist and cellular biologist at the Leiden University Medical Center in the Netherlands. Her research aims to obtain…

Topas Therapeutics Serves as Exclusive Translational Partner for Collaborative Research Center Focused on Liver Inflammation at University Medical Center Hamburg-Eppendorf

Funding for Collaborative Research Center (CRC) 841 at University Medical Center Hamburg-Eppendorf (UKE) extended for 4 years in the amount of nearly EUR 15 million. Topas Therapeutics will act as exclusive partner for indication expansions and translation of research results into clinical development. Hamburg, 25th…